- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06174025
Validity and Reliability of the 6 Minute Pegboard Ring Test
Validity and Reliability of the 6 Minute Pegboard Ring Test in Duchenne Muscular Dystrophy Patients
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Şahinbey
-
Gaziantep, Şahinbey, Turkey, 27000
- Gaziantep Islamic Science and Technology University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Volunteering to participate in the research,
- Being diagnosed with Duchenne muscular dystrophy between the ages of 6-17,
- Being Level 1 and 2 according to the Brooke Upper Extremity Functional Classification Scale
- Having no problems reading and/or understanding the scales and cooperating with the tests to be.
- Ability to sit independently for approximately 15 minutes during the evaluation
Exclusion Criteria:
- Not volunteering to participate in the research,
- Having any orthopedic problem in the upper extremity,
- A neurological disease or other clinical condition that may affect cognitive status having a diagnosis,
- Having had surgery on the upper extremities in the last 6 months and any having an injury
- At a level that prevents functional activities in the upper extremity Having severe contractures (joint restriction)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
6 Minute Pegboard and Ring Test
Time Frame: A total of two measurements will be made at 1-week intervals within 6 months.
|
The 6-minute pegboard and ring test is used to assess upper extremity functional capacity.
The patient sat in front of a perforated board with bottom pegs at shoulder level.
The upper pegs are placed in the hole 20 cm above the lower pegs.
10 rings of the same size are placed on the lower pegs.
The patient is asked to move as many rings as possible from the lower pegs to the upper pegs and vice versa within a 6-minute period.
Pulse, blood pressure, SpO₂, dyspnea and arm fatigue detection are recorded before/after each test.
Before the actual test, patients are allowed to move up and down the rings in a cycle to become familiar with the testing procedure.
If the patient wants to rest during the test, he is allowed, but the stopwatch is not stopped.
During the test, standard encouraging phrases are said to the patient at the end of each minute.
|
A total of two measurements will be made at 1-week intervals within 6 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quick Shoulder-Hand Syndromes Questionnaire
Time Frame: A total of two measurements will be made at 1-week intervals within 6 months.
|
The Quick Shoulder-Hand Syndromes Questionnaire is used to evaluate musculoskeletal physical function and symptoms of the upper extremity.
The survey consists of 11 items and is scored between 0-100 points.
Higher scores indicate more disability
|
A total of two measurements will be made at 1-week intervals within 6 months.
|
|
Assessment of muscle strength
Time Frame: A total of two measurements will be made at 1-week intervals within 6 months.
|
Muscle strength will be measured using a digital dynamometer (Manual Muscle Tester™), shoulder flexor, shoulder abductor, elbow extensor and elbow flexor muscle strength.
Muscle tests will be repeated three times for each side and the highest value will be recorded in kg.
Muscle strength will be calculated as percentages of expected values.
|
A total of two measurements will be made at 1-week intervals within 6 months.
|
|
The Pediatric Quality of Life Inventory
Time Frame: A total of two measurements will be made at 1-week intervals within 6 months.
|
The health-related quality of life of the participants will be evaluated with the Turkish version PedsQL-3.0
Neuromuscular Module.
The scale consists of 3 categories containing 25 items.
These categories; It includes 17 items regarding the disease process and related symptoms, 3 items regarding communication skills, and 5 items regarding the family's financial and social support systems.
The items of the scale are scored between 4 (always poses a problem) and 0 (never poses a problem).
At the end of the scale, a score between 0 and 4 is made.
A score close to 100 indicates that the health-related quality of life is at a better level.
|
A total of two measurements will be made at 1-week intervals within 6 months.
|
|
Brooke Upper Extremity Functional Classification Scale
Time Frame: A total of two measurements will be made at 1-week intervals within 6 months.
|
It will be used to evaluate the upper extremity functional level of the individuals who will be included in the study. It was developed to determine the functional level of the upper extremity in the clinical evaluation of DMD (11). The steps of this scale are as follows; Level 1: Begins to move with the arms at the sides and can fully clasp the hands above the head. Level 2: However, he can bring his arms above his head by flexing his elbows or use his accessory muscles Level 3: He cannot raise his hands above his head, but he can bring the glass to his mouth (uses both hands if necessary). Level 4: He can raise his hands to his mouth, but cannot lift a glass of water to his mouth. Level 5: Cannot raise hands to mouth, but can raise hands to hold a pen or pick up a coin from the table. Level 6: He cannot raise his hands up to his mouth and cannot use his hands functionally. |
A total of two measurements will be made at 1-week intervals within 6 months.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Çağtay MADEN, PhD, Gaziantep Islamic Science and Technology University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023/236
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duchenne Muscular Dystrophy
-
Dyne TherapeuticsRecruitingMuscular Dystrophies | Muscular Dystrophy, Duchenne | Duchenne Muscular Dystrophy (DMD) | Muscular Dystrophy, Duchenne and Becker Types | Genetic Disease, X-Linked | Genetic Disease, Inborn | DMD | Congenital, Hereditary, and Neonatal Diseases and Abnormalities | Muscular Dystrophy (DMD) | Muscular Dystrophies... and other conditionsUnited States
-
Cairo UniversityCompletedMuscular Dystrophy, Duchenne TypeEgypt
-
Chaitanya Hospital, PuneUnknownMuscular Dystrophy | Duchenne Muscular Dystrophy,India
-
Universitaire Ziekenhuizen KU LeuvenRecruitingDuchenne Muscular Dystrophy (DMD)Belgium
-
Peking Union Medical College HospitalActive, not recruitingDuchenne Muscular Dystrophy (DMD)China
-
PTC TherapeuticsCompletedNonsene Mutation Duchenne Muscular DystrophyUnited States
-
Ondokuz Mayıs UniversityCompletedDuchenne Muscular Dystrophy (DMD)Turkey
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
Parent Project, ItalyCompletedDuchenne Muscular Dystrophy (DMD)Italy
-
GenethonInstitute of MyologyCompletedDuchenne Muscular Dystrophy (DMD)France